• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast

    4/29/25 7:30:00 AM ET
    $CODX
    Medical/Dental Instruments
    Health Care
    Get the next $CODX alert in real time by email

    SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.

    The conference call and webcast will be available via:

    Webcast: ir.codiagnostics.com on the Events & Webcasts page, or accessible directly here

    Conference Call: 800-715-9871 (Toll Free) or (646) 307-1963 (Toll) with participant passcode 1977478

    If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.

    About Co-Diagnostics, Inc.

    Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease.

    Investor Relations Contact:

    Andrew Benson

    Head of Investor Relations

    +1 801-438-1036

    [email protected]



    Primary Logo

    Get the next $CODX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CODX

    DatePrice TargetRatingAnalyst
    8/12/2022$5.00Buy → Neutral
    Sidoti
    12/29/2021$14.00Buy
    Sidoti
    11/12/2021$16.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CODX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference

      Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that they will be participating in the D. Boral Capital ("DBC") Inaugural Global Conference on May 14, 2025 in New York City. The DBC conference connects emerging growth issuers across multiple sectors with institutional investors. Company representatives will be participating in one-on-one meetings to introduce institutions to the Company's value proposition and to the upcoming Co-Dx PCR* testing platform. More information about the conferen

      5/14/25 9:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results

      SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Results:  ●Revenue of $0.1 million, which declined from $0.5 million during the Q1 2024 primarily due to timing of grant revenue recognition. The Company did not recognize any grant revenue during the first quarter 2025    ●Operating expenses of $8.6 million decreased by 18.2% from the prior year first quarter    ●Operating loss of $8.6 million compared to operating loss of $10.3 million in Q

      5/8/25 4:01:00 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast

      SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations. The conference call and webcast will be available via: Webcast: ir.codiagn

      4/29/25 7:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care

    $CODX
    SEC Filings

    See more
    • Co-Diagnostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Co-Diagnostics, Inc. (0001692415) (Filer)

      5/29/25 4:30:38 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Co-Diagnostics Inc.

      10-Q - Co-Diagnostics, Inc. (0001692415) (Filer)

      5/8/25 4:10:37 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Co-Diagnostics, Inc. (0001692415) (Filer)

      5/8/25 4:05:13 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care